You just read:

U.S. FDA Accepts for Review Astellas' Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

News provided by

Astellas Pharma Inc.

Sep 12, 2017, 22:00 ET